The main aim of the trial is to assess the long‑term safety of the study drug, meaning how well it is tolerated over time and what side effects may occur. Participants who have already finished earlier studies receive the medication for an extended period, attending regular visits where health checks, blood tests and simple scans are performed. Any unwanted problems, called adverse events, are recorded and evaluated, with particular attention to serious issues that might require medical care.

The purpose of the study is to evaluate how well these new immunotherapy combinations work compared to Pembrolizumab alone in patients with a specific type of NSCLC that shows high levels of a protein called PD-L1. This protein can affect how the immune system responds to cancer. The study will involve participants receiving these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period of time to observe the effects of the treatments on their cancer.

Participants in the study will be monitored closely by healthcare professionals to ensure their safety and to gather information about how the treatments are working. The study aims to provide valuable insights into the effectiveness of these new treatment combinations for NSCLC, potentially leading to better treatment options for patients in the future.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.

The study will use different combinations of these medications. Some participants will receive both mirikizumab and tirzepatide, while others will receive mirikizumab and a placebo. Both medications are given as injections under the skin, except in some cases where mirikizumab may be given through a vein. The treatment will continue for 52 weeks, which is approximately one year.

The study will measure how well the medications work together to achieve three main goals: reducing Crohn’s Disease symptoms, healing the inside of the digestive tract, and helping participants lose weight. The amount of tirzepatide used in the study may be adjusted up to 15 milligrams, depending on how well it is tolerated.

The treatment being studied involves a combination of two medications: MK-1084 and pembrolizumab. Pembrolizumab is also known by the brand name KEYTRUDA and is given as an infusion, which means it is delivered directly into the bloodstream through a vein. MK-1084 is taken as a tablet. Some participants in the study will receive pembrolizumab with MK-1084, while others will receive pembrolizumab with a placebo, which looks like the real medication but does not contain any active ingredients. The purpose of the study is to compare the effectiveness of these two treatment combinations.

Participants in the study will receive their assigned treatment and will be monitored over a period of time to see how their cancer responds. The study will look at how long participants live without their cancer getting worse, known as progression-free survival, and overall survival, which is the length of time participants live after starting the treatment. The study will also track any side effects experienced by participants and how the treatment affects their quality of life. This information will help researchers understand the potential benefits and risks of the new treatment combination for people with this specific type of lung cancer.

The main goal of the study is to see whether the new combination works better and is safe compared with the single drug. Participants will receive their assigned injection at regular visits over about one year, and they will come to the clinic for check‑ups, blood tests, and questionnaires about symptoms. The study is double‑blind, meaning neither the participants nor the doctors know which treatment is being given, to keep the results unbiased.

The key result the researchers are looking for is clinical remission at week 48, which means the person’s symptoms have cleared enough that they no longer need daily medication for the disease. Throughout the trial, safety will be monitored by checking for any side effects or changes in health.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

The purpose of the study is to determine which of these treatments leads to a shorter stay in the hospital for patients whose infection does not improve with the initial antibiotics and drainage. After a patient is enrolled, they receive either the surgical procedure or the medication combination, stay in the hospital while doctors watch for improvement, and are then followed for about a month to see how quickly they can leave the hospital and return to normal activities.

During the follow‑up, information is collected on how long the chest tube remains, any need for additional procedures, pain levels, ability to perform daily tasks, and overall quality of life. The study also looks at the costs related to health care and any loss of work time, helping to understand the broader impact of each treatment option.

The purpose of the study is to determine which of the two therapies works better at controlling the disease. Participants will be randomly assigned to receive one of the two treatments, followed by regular check‑ups that may include scans such as positron emission tomography-computed tomography to look for any remaining cancer and assessments of overall health and quality of life. The study continues for several months after treatment to monitor how well the disease is controlled and to record any side effects.

The main aim of the study is to evaluate how safe and well‑tolerated multiple doses of the medicine are in this patient group. Participants will receive a series of injections over several weeks, with regular clinic visits where vital signs, heart rhythm checks, and blood tests are performed to watch for any unwanted effects. Some participants may receive a harmless inactive substance for comparison, but the study staff will not know which person receives which treatment.

During the study period, blood samples are taken to measure the activity of the clotting protein that is low in this condition, and menstrual blood loss is recorded using a simple diary that helps estimate the amount of blood lost each cycle. After the dosing phase, participants continue to be followed for a short time to ensure any delayed effects are captured. All procedures are designed to be as short and comfortable as possible.

Participants who have finished first‑line chemotherapy and are either in complete remission (no detectable cancer) or have stable disease are randomly assigned to one of the two groups. They take the study medication daily for a defined period while regular check‑ups, scans, and questionnaires about quality of life are performed. The study follows each participant for several years to record any return of cancer, new health problems, or death, and the information is used to compare the two treatment approaches.

The main goal of the trial is to find out whether this intranasal stem cell therapy can safely reduce brain injury and improve motor abilities in affected infants. Babies with a confirmed diagnosis on a brain scan are randomly assigned to receive either the stem cell drops or a placebo that looks the same but contains no active cells. Over the next two years, the children are monitored for safety, including regular check‑ups and brain imaging using MRI, a technique that creates detailed pictures of the brain without surgery.

Developmental progress is measured with the Bayley-IV-NL motor score at 24 months, which evaluates how well a child can move and control muscles. Additional assessments look at thinking skills, the presence of cerebral palsy, seizures, and vision or hearing problems. Families also complete questionnaires about quality of life, and any serious health events are recorded throughout the study period.

The purpose is to find out whether adding this hormone support increases the chance of a baby being born alive compared with taking no active medication. Participants are randomly assigned to receive either the hormone capsule or the placebo for up to six months while trying to become pregnant naturally. Pregnancy outcomes, any side effects, and quality of life are recorded, and participants are followed for up to 18 months after the start of the study.

The purpose is to evaluate the safety and tolerability of single doses of the study drug. After receiving one injection, participants are monitored for several weeks to track any side effects and to assess how the drug moves through the body (pharmacokinetics) and how it influences bodily functions (pharmacodynamics). The trial uses a randomized, double‑blind design, meaning neither the participants nor the study staff know which injection is the active drug or the placebo, and it includes a short series of visits for screening, dosing, and follow‑up assessments.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The purpose of the study is to compare how long patients stay free of disease progression when venetoclax is continued for a longer period versus stopping after the initial six‑month course. After the six cycles of the combination, participants are randomly assigned—by chance—to either keep taking venetoclax for up to about 20 cycles or to stop the drug. All participants are then monitored with regular doctor visits, blood tests, and scans to check for any return of disease or side effects. The main outcome measured is progression free survival, which counts the time from random assignment until the disease gets worse or the patient dies.

The trial is testing an oral capsule called NB-4746 and also includes the already approved medicine Riluzole. Some participants will receive a dummy pill, known as a placebo, so that researchers can compare how the real medicines work. The main goal of the study is to find out whether the new drug is safe for people with the disease, meaning it does not cause unacceptable side effects.

People who join the study will take the assigned capsule each day and will visit the clinic several times for simple check‑ups. During these visits doctors will look at basic health information such as blood pressure and heart rate, draw small amounts of blood for laboratory testing, and perform a quick heart rhythm test. The early part of the study lasts about four weeks, and later phases continue for a longer period to keep monitoring safety.

The purpose of the study is to evaluate whether the new medicine can lower the number of treated bleeds compared with standard therapy. Participants will be assigned to receive either the new medicine or the standard factor VIII for about six months, attending regular visits where any bleeding events are recorded, quality‑of‑life questionnaires are completed, and safety checks such as blood tests for antibodies or reactions at the injection site are performed. The trial will monitor how often injections are needed, the amount of medicine used, and any side effects that arise during the treatment period.

The purpose of the trial is to determine whether NXT007 works at least as well as Emicizumab in preventing bleeds. Participants receive regular injections for several months and attend scheduled visits where doctors check their health, collect blood samples, and ask about daily activities and quality of life. The main way the study measures success is by counting the average number of bleeding episodes that need treatment each year, called the annualized number of treated bleeds.

Throughout the study, safety is closely watched. Researchers look for any side effects such as reactions at the injection site, allergic responses, or signs of clotting problems. Participants also complete simple questionnaires about how their condition affects everyday life, helping to assess both the medical and personal impact of the treatments.

The study is testing whether adding the experimental oral drug pelabresib (code name DAK539) to the approved oral medication ruxolitinib improves reduction of spleen size and relief of symptoms compared with taking ruxolitinib together with a placebo. The purpose of the study is to determine if the combination therapy provides a greater benefit than the standard treatment alone.

Participants will take the study tablets each day for several months. Throughout the trial they will undergo imaging tests, such as MRI or CT scan, to measure the size of the spleen, and they will complete simple questionnaires about how they feel. Regular health checks will be performed to monitor safety, and the study will continue for about a year to observe how the treatment works over time.

The purpose of the study is to see whether a precision‑medicine strategy that combines these targeted drugs can improve the rate of blood‑cell recovery, known as hematologic remission, compared with standard approaches. Hematologic remission means that the abnormal blood cells are reduced to very low levels, indicating that the leukemia is under control.

Participants are randomly assigned to receive either the personalized drug combination or the standard treatment. After starting therapy, they will have regular clinic visits and simple blood tests over several months to monitor response and any side effects. The study continues for a period that allows researchers to observe how long the response lasts and whether the disease returns.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The study compares children who receive anakinra plus usual care with information from a past group of similar patients who received usual care only. The course of the study is simple: treatment is started early during the intensive care stay, and the children are then followed during the hospital stay and for about 28 days to see how they do. Safety is also checked, including possible side effects and signs of liver problems, new infections, and other serious health changes.

Participants will take asciminib during the study and will have regular study visits over time. The study will follow how the disease responds, how long the response lasts, and whether the treatment causes side effects. Growth and development will also be checked, including height or length, weight, bone growth, and puberty changes. The study is planned as a single-group trial, so all participants receive the same study treatment.

The purpose of the study is to evaluate PFS at 12 months compared with historical results. After the first infusion, patients return for regular treatment sessions over several months while doctors monitor the cancer for any signs of growth or spread, record any side effects that are related to the immune system, and assess overall well‑being. PFS means the length of time a person lives without the disease getting worse. Immune‑related side effects are reactions that happen because the treatment activates the body’s own defenses, and quality of life refers to how a person feels and functions during the study.

The purpose of the study is to determine whether this cell‑based therapy can improve how long patients live without the disease getting worse and ultimately increase overall survival. After the chemotherapy course, the cell infusion is administered, followed by surgery to remove the tumor when possible. Patients are then monitored over time to see if the cancer returns, using imaging criteria called RECIST 1.1, and to assess quality of life and safety. The follow‑up period includes regular doctor visits, scans, and blood tests to track the immune response and any side effects.

People in the study are assigned by chance to receive either RO7795068 or placebo, and neither the participants nor the study team know which one is being given. The study lasts for about 72 weeks. During this time, the treatment is given regularly, and the study team checks body weight, general health, and possible side effects. The study also looks at changes in waist size, blood sugar, blood fats, blood pressure, eating habits, and quality of life.

Possible side effects, changes in blood tests, heart tracing results, and other safety checks are monitored throughout the study. The trial is designed to find out whether RO7795068 can help with weight management in adults with obesity or overweight who do not have type 2 diabetes.

People in the study are assigned by chance to one of the eye drop groups. The study lasts for several weeks, and the eye is checked during treatment and again afterward to see whether healing has been maintained. The main focus is whether the damaged eye surface closes and stays healed over time.

Some people in the study may also receive NETSPOT (dotatate) for a special body scan, and LysaKare (arginine hydrochloride, lysine hydrochloride) may be given to help protect the kidneys during treatment with Lutathera. The study also includes checks for side effects and general safety, and treatment may be stopped or changed if the medicine is not tolerated. This trial is focused on newly diagnosed extensive stage small cell lung cancer and uses a combination of cancer medicine, immune treatment, and a targeted radioactive medicine.

The study follows a treatment course made up of several phases. At first, treatment is given to bring the leukemia under control. After that, more treatment is given over time to help keep the disease from returning. Some children may receive only the main drug combination, while others may receive an added medicine based on the type of APL and the level of risk. During the study, doctors watch for side effects and monitor how the disease responds to treatment.

The study is designed for newly diagnosed APL in children and adolescents and compares treatment approaches for different risk groups. The study also examines whether the treatment causes any serious problems and how long children stay in the hospital during therapy.

The purpose of the study is to see whether using indocyanine green during surgery helps the team find and remove more lymph nodes (small glands that are part of the body’s immune system) and whether this changes the surgery in any helpful or harmful way. Some patients will have surgery with the dye and the special light imaging, while others will have the same type of surgery without it. The study includes operations such as nephroureterectomy (removal of a kidney and the tube that carries urine from it) and retroperitoneal lymph node dissection (removal of lymph nodes from the back part of the abdomen).

During the study, the dye is given before or during surgery, and the surgical team then carries out the planned operation and removes tissue as needed. After surgery, the medical team checks for any side effects from the dye and watches for usual surgery-related problems during recovery. The study also looks at how the surgery went overall and how well the dye appeared to help during the procedure.

The purpose of the study is to evaluate the safety and effectiveness of a combination of treatments. The experimental treatment includes the drug asciminib, which is taken by mouth, alongside chemotherapy, a type of treatment using strong medicines to kill cancer cells. Following this, the drug blinatumomab, which is given through an IV infusion, may be used. Other medications that may be part of the background care include vincristine sulfate, dexamethasone, cytarabine, methotrexate, hydrocortisone, and prednisolone acetate.

The study is divided into different stages to find the most appropriate dose of the medicine. In the first stage, researchers look at how the body reacts to different amounts of the drug to ensure safety. In the second stage, the focus shifts to determining how many patients achieve complete remission, a state where all signs of cancer have disappeared. Throughout the process, doctors will monitor for any side effects or changes in health to ensure the treatment is managed carefully.

The research is divided into two parts. The first part involves a one-day treatment to see how the medications affect the virus within certain cells. The second part involves a four-week treatment to evaluate if the combination of drugs can reduce the overall amount of viral genetic material, known as HIV-DNA, present in the body. Participants may receive the active medications or a placebo.

The study uses an investigational product called MaaT013, which is a preparation of allogeneic faecal microbiota, pooled given as a rectal solution. This means that healthy bacteria taken from several donors are mixed together and introduced into the lower intestine to help restore a normal balance of gut microbes. In addition, participants may receive the antibiotic vancomycin taken by mouth to control any unwanted bacteria while the new microbes settle in.

The purpose of the research is to find out whether MaaT013 can be given safely and is tolerated by pediatric and adolescent participants, and whether it can be administered feasibly in this age group. Participants receive the study medication at scheduled visits and are monitored for side effects, ability to keep the solution in the rectum for the required time, and changes in stress or anxiety. Follow‑up visits continue for up to twelve months, during which physicians check for improvement in gastrointestinal symptoms, the need for additional medicines, and overall health status.

After giving consent, participants are randomly assigned to either the standard fludarabine dosing group or the target‑level dosing group. All patients then undergo the CAR T cell infusion and are followed for several months to monitor how long they remain free of disease progression, need for new leukemia treatment, or other serious complications. Visits include routine check‑ups, blood tests, and simple questionnaires about how they feel, allowing researchers to see whether the adjusted dosing improves outcomes and safety.

The new medication, identified by the code name INCB123667, is given as a tablet taken by mouth each day. Participants may receive one of several standard chemotherapy options chosen by their doctor, including paclitaxel, topotecan, gemcitabine, or doxorubicin, all of which are administered through an intravenous (IV) infusion, meaning the drug is delivered directly into a vein.

After enrollment, participants are assigned to receive either the study pill or one of the IV chemotherapy drugs and are followed with regular clinic visits, imaging scans to check tumor size, blood tests, and quality‑of‑life questionnaires for several months. The trial will record how long patients live without the disease getting worse, known as progression‑free survival, and how long they live overall, referred to as overall survival, to evaluate the relative benefit of the treatments.

The main goal is to determine whether the medicine can be given safely, to identify the appropriate dose, and to see early signs that it may shrink or control the tumors.

Participants will take the capsule by mouth on a regular schedule. In the first part of the trial, the dose is adjusted to find the level that is tolerated without serious side effects. In the second part, patients with colorectal cancer or endometrial cancer receive the selected dose and are monitored with routine visits, blood tests, and imaging scans to check for tumor response and any side effects.

During the study, researchers will monitor levels of a specific substance, MTX-PG, in the red blood cells. This substance is a byproduct of the medication that stays in the blood and can indicate how much medicine is actually active in the body. Participants will undergo regular check-ups to track their health and the effectiveness of the treatment over several months.